Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Willis
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
Abstract Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I3LUNG (NCT05537922) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based study, enrolling 2,396 patients.
Letter: w/o Trump: God Bless America, w/Trump: God Help us
Hopefully, Trumps final "gift to America": Pete Hegseth, Incompetence wrapped in Arrogance. Michael Willis Green Valley Disclaimer: As submitted to the Arizona Daily Star. Follow these steps to easily submit a letter to the editor or guest opinion to the Arizona Daily Star. Respond: Write a letter to the editor | Write a guest opinion Subscribe to stay connected to Tucson. A subscription helps you access more of the local stories that keep you connected to the community.
Biomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026
Biomed Industries, Inc- logo Biomed Industries Presents Promising Phase 2/3 Clinical Results of NA-921 for Rett Syndrome at Orphan Drug Summit 2026 Advancing Named Patient Access Initiative Children with Rett syndrome urgently need better therapies. We are advancing Phase 3 while expanding global Named Patient access to bring NA-921 to eligible patients as quickly as possible” — Dr. Lloyd L.
Biomed Industries Presents Phase 3 Programs of NA-931 Alone and Combining With Oral Semaglutide for Obesity at ADA 2026
Biomed Industries, Inc- logo Biomed Industries Presents Global Phase 3 Programs of NA-931 as Monotherapy and in Combination With Oral Semaglutide for Obesity at ADA 2026 in New Orleans Obesity requires lifelong management. NA-931 may offer a promising maintenance therapy after GLP-1 discontinuation.” — Dr. Lloyd L.
Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue and NA-931 Phase 3 Launch
Biomed Industries, Inc- logo Biomed Industries, Inc. Advances Dual-Track Obesity Therapy Strategy with Near-Term Revenue from Bioxentra Life Sciences, Inc. and NA-931 Phase 3 Launch Winning in this market requires both speed and differentiation. Our model generates near-term revenue while advancing a potentially best-in-class therapy to drive scalable, long-term value creation.” — Dr. Lloyd L.
Biomed Industries Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity & Cardiovascular Diseases
Biomed Industries, Inc- logo NA-831 for Alzheimer's Disease Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular Disease at Global Neuroscience Summit 2026 With the Unified Theory integrating brain, metabolic, and cardiovascular systems, we can fundamentally reshape disease treatment and significantly improve outcomes for millions of patients worldwide” — Dr. Lloyd L.
Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week
Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week Biomed Industries, Inc- logo Biomed Industries, Inc.
Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity
Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as monotherapy and in combination with semaglutide and tirzepatide underscores our strategy to deliver durable weight loss with lean mass preservation.” — Dr. Lloyd L.
Biomed Industries to Present Four Transformative Studies on Alzheimer’s Disease, Obesity, and Stroke at CTAD 2025
Biomed Industries to Present Four Transformative Studies on Alzheimer’s Disease, Obesity, and Stroke at CTAD 2025 Biomed Industries, Inc- logo NA-831 for Alzheimer's Disease Biomed Industries to Present Four Transformative Studies on NA-831 for Alzheimer’s Disease, NA-931 for Obesity, and NA-911 for Stroke at CTAD 2025 - San Diego NA-831 is the only drug to date that has halted disease progression in Phase 2 clinical trials.
Biomed Industries to Present Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025
Biomed Industries to Present Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025 Biomed Industries, Inc. logo Biomed Industries, Inc. to Present Breakthrough Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025 NA-931, the first-in-class oral quadruple agonist represents a major leap forward for treating obesity, offering patients a convenient, effective, and safer alternative to existing GLP-1 therapies” — Dr. Lloyd L.
Site-Selective C-H Sulfinamidation through Electron-Donor-Acceptor Complex Photoactivation and Radical Addition into Sulfinylamine Reagents | Organic Letters
Organic Letters Cite this: Org. Lett. 2025, XXXX, XXX Click to copy citationCitation copied! . This publication is licensed under CC-BY 4.0 . You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.
Biomed Industries, Inc. to Present Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS 2025
Biomed Industries, Inc- logo Biomed Industries, Inc. to Present Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS Conference, October 18-20, 2025 in Lisbon, Portugal. The Phase 2/3 results of NA-921 show strong potential as an effective, well-tolerated treatment with a favorable safety profile, promising better patient adherence and improved long-term outcomes” — Dr. Lloyd L.
Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: an Oral Quadruple Receptor Agonist for Obesity at EASD 2025
Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: an Oral Quadruple Receptor Agonist for Obesity at EASD 2025 Biomed Industries, Inc- logo Biomed Industries, Inc. Unveils Phase 2 Success of NA-931: a First-in Class Oral Quadruple Receptor Agonist for the Treatment of Obesity at EASD 2025 in Vienna The Phase 2 results show NA-931 as a safe and effective oral weight-loss therapy.
Biomed Industries to Present Phase 2 Results on NA-931-An Oral Alternative to Injectables for Obesity- EASD 2025 Austria
Exponential Interactive, Inc d/b/a VDX.tv Cookie duration: 90 (days). Data collected and processed: IP addresses, Device identifiers, Probabilistic identifiers, Browsing and interaction data, Non-precise location data, Users’ profiles, Privacy choices more Cookie duration resets each session. View details | Storage details | Privacy policy Consent Cookie duration: 395 (days).
Iron-Catalyzed Decarboxylative Sulfinylation of Alkyl Carboxylic Acids
Organic Letters Cite this: Org. Lett. 2025, XXXX, XXX Click to copy citationCitation copied! . This publication is licensed under CC-BY 4.0 . You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator.
Biomed Industries to Present Pivotal Studies at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies
Biomed Industries to Present Pivotal Studies at Paris MASH 2025 with Breakthrough in Obesity and Liver Disease Therapies Company to present clinical trial protocols for NA 941 and cross indication data readouts for NA 931/NA 941 supporting development in obesity and MASH. We are excited to advance NA 941 oral therapies to address MASH at its metabolic roots while improving patient quality of life across metabolic disease.” — Dr. Lloyd L.
Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 and Semaglutide Combination Therapy for Treating Obesity
Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 and Semaglutide Combination Therapy for Treating Obesity Biomed Industries, Inc- logo Biomed Industries, Inc. Advances First-of-Its-Kind Oral NA-931 (Bioglutide) and Injectable Semaglutide Combination Therapy for the Treatment of Obesity Phase 2 data show NA-931 has meaningful efficacy and excellent safety/tolerability profile.
Biomed Industries Presents Four Breakthrough Studies on Alzheimer’s, Rett Syndrome, and Obesity Therapies at AAIC 2025
NA-831 for Alzheimer's Disease Biomed Industries, Inc. Presents Four Pivotal Studies at AAIC 2025 Highlighting Breakthrough Therapies for Alzheimer’s, Rett Syndrome, and Obesity NA-831 is the only drug to date that has halted Alzheimer’s disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.” — Dr. Lloyd L.
Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025
Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025 Biomed Industries, Inc- logo Biomed Industries, Inc. Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Receptor Agonist for the Treatment of Obesity at ENDO 2025 NA-931 showed excellent safety and efficacy in Phase 2 as a first-in-class oral quadruple agonist.
WNBA Odds, Picks, and Props
By: Mike Willis WNBA Odds and Props: Indiana Fever and Minnesota Lynx Favored in Saturday Matchups Gainbridge Fieldhouse and Target Center will be the settings for a pair of WNBA contests tonight, with the Indiana Fever and Minnesota Lynx entering their respective games as home favorites. The Los Angeles Sparks will travel to Indianapolis to take on the Fever in a rematch, while the Golden State Valkyries face a tough road test against league best the Minnesota Lynx in Minneapolis.
Biomed Industries, Inc. to Present Phase 2 Results of Oral Obesity Drug NA-931 and Host Press Conference at ADA 2025
Biomed Industries, Inc. to Present Phase 2 Results of Oral Obesity Drug NA-931 and Host Press Conference at ADA 2025 Biomed Industries, Inc- logo Biomed Industries, Inc. to Present Phase 2 Results of NA-931, a First-in-Class Oral Therapy for Obesity, and Host a Press Conference at the ADA 025 Phase 2 results confirm NA-931’s strong efficacy and safety as a first-in-class oral obesity therapy.
Biomed Industries, Inc. to Unveil Unified Acceleration Platform at ADA 2025, Linking Alzheimer’s, Obesity, and Diabetes
Biomed Industries, Inc. to Unveil Unified Acceleration Platform at ADA 2025, Linking Alzheimer’s, Obesity, and Diabetes Biomed Industries, Inc- logo NA-831 for Alzheimer's Disease Biomed Industries, Inc.
Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025
Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025 Biomed Industries, Inc. logo Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Medicine Alternative to Injectables for Obesity—at ADA Conference 2025 in Chicago We believe the future of obesity treatment lies in safe, effective, and accessible oral therapies.
Asymmetric reductive arylation and alkenylation to access S-chirogenic sulfinamides - Nature Communications
Abstract The study of the stereochemistry of organic sulfur compounds has been ongoing for over a century, with S-chirogenic pharmacophores playing an essential role in drug discovery within bioscience and medicinal chemistry. Traditionally, the synthesis of sulfinamides featuring stereogenic sulfur(IV) centers involves a complex, multistep process that often depends on chiral auxiliaries or kinetic resolution.
Letter: Political humor
Apparently, last Sundays' writer (Post Election 2024: Send in the clowns), forgot the rest of the song: Don't bother, they're already here. Michael Willis Green Valley Disclaimer: As submitted to the Arizona Daily Star. Video Player is loading. Current Time 0:00 Duration -:- Remaining Time --:- Beginning of dialog window. Escape will cancel and close the window. End of dialog window. Respond: Write a letter to the editor | Write a guest opinion Subscribe to stay connected to Tucson.
Standard Terminology for Peer Review: Where Next?
At the 2023 ISMTE Global Event, I spoke about the Standard Terminology for Peer Review in a session entitled ‘Creating agreed standards in journal publishing.’ This article builds on that presentation and provides an update on progress since then. By way of historical context, although the term ‘peer review’ dates from the 1970s1, the concept of consulting learned experts for an opinion on someone’s research has existed for far longer.
Prospective observational study of peripheral intravenous cannula utilisation and frequency of intravenous fluid delivery in the emergency department-Convenience or necessity? | PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Willis M, Colonetti E, Bakir A, Alame YJ, Annetts M, Aygin DT, et al. (2024) Prospective observational study of peripheral intravenous cannula utilisation and frequency of intravenous fluid delivery in the emergency department—Convenience or necessity? PLoS ONE 19(6): e0305276.
Dutton's nuclear policy a disaster for Australia - The AIM Network
Written by: The AIM Network Leave a reply Category: Politics permalink Climate Council Media Release Responding to reports today that Opposition Leader Peter Dutton would rip up Australia’s 2030 climate targets if elected, Climate Council CEO Amanda McKenzie said: “Dutton’s climate policy is a disaster, and the consequence for Australians would be more extreme heat, fires and floods.
A Detectable Subservience - The AIM Network
Written by: The AIM Network Leave a reply Category: AIM Extra permalink By Michael Willis The first operational outcome of the Pillar 2 AUKUS arrangement between the US, UK and Australia has just been announced. The three countries will share data from their submarine-hunting PA-8 Poseidon aircraft, manufactured by the troubled Boeing Corporation.
Sandmeyer Chlorosulfonylation of (Hetero)Aromatic Amines Using DABSO as an SO2 Surrogate
Download Hi-Res ImageDownload to MS-PowerPointCite This:Org. Lett. 2024, XXXX, XXX RETURN TO ARTICLES ASAPPREVLetterNEXT Lucia Pincekova Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford OX1 3TA, U.K. , Aurélien Merot Chemistry Process R&D, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland , * , and * Cite this: Org. Lett. 2024, XXXX, XXX rapid-communication ACS Publications.
Biomed Industries, Inc. to showcase its research at Clinical Trials on Alzheimer’s Disease Conference 2023 in Boston
Biomed Industries, Inc- logo Biomed highlights failure of anti-amyloid drugs, presenting new neurogenesis hypothesis and clinical results of NA-831 for treatment of Alzheimer's disease Even if we can develop drugs that reduce amyloid beta, they will not reverse the damage. Clinical results of NA-831 show that adult neurogenesis in the hippocampus could potentially right that wrong” — Lloyd Tran SAN JOSE, CA, USA, October 4, 2023 / EINPresswire.com/ -- Biomed Industries,™ Inc.
SNM Radiation Signature Classification Using Different Semi-Supervised Machine Learning Models
Author / Affiliation / Email Search Type Submit to this Journal Review for this Journal Edit a Special Issue Article Menu /ajax/scifeed/subscribe Altmetric share Share announcement Help format_quote Cite thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services.
The Past and the Future of Algeria’s Hirak Protests
Social and political tensions did indeed erupt onto the streets, in 2019, but these took a shape and character few had anticipated. In notable contrast to protests over the previous decades, the mass protests starting in 2019 did not seek to articulate either a well-established and defined ideological platform, or one linked to assertions of linguistic, cultural or religious identity.
Transient ice loss in the Patagonia Icefields during the 2015–2016 El Niño event - Scientific Reports
Abstract The Patagonia Icefields (PIF) are the largest non-polar ice mass in the southern hemisphere. The icefields cover an area of approximately 16,500 km2 and are divided into the northern and southern icefields, which are ~ 4000 km2 and ~ 12,500 km2, respectively. While both icefields have been losing mass rapidly, their responsiveness to various climate drivers, such as the El Niño-Southern Oscillation, is not well understood.
Decentralizing proxy power
The creation of index funds is arguably the most successful innovation in modern financial history. Index funds hold rock star status with investors who love their simplicity, performance, and low costs. Their near-universal popularity, however, has presented investors with a new dilemma. If current trends continue, it’s only a matter of time before index funds own more than half of all U.S. stocks. Why is that a problem?
Conducting and Interpreting Results of Network Meta-Analyses in Type 2 Diabetes Mellitus: A Review of Network Meta-Analyses That Include Sodium Glucose Co-transporter 2 Inhibitors
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 PRISMA flow diagram of literature search results. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Fig. 2 Number of network meta-analyses including drugs from classes other than SGLT2 inhibitors.
Getting over bad/disappointing results at Uni
Offline 0 Am currently studying a masters degree at uni, and fortunately my first semester went brilliantly with all results being distinctions. However, my second semester went rather poorly, to which I received 3 Merits, a pass, and few distinctions. I have taken these results a lot more personally than expected, and my semester 2 results have had a negative inpact on me, and I feel exhausted, deflated, disappointed, ashamed, embarrassed and angry.
Hello, my name is Michael Willis!
Hello, my name is Michael Willis! Offline 0 I'm studying... MSc Computer Science I'm interested in... - Computing - Comics - Food (places to try and cooking) My study level is...
Under the Gaze of Kali: Exhibitionism in the Kalighat Painting Exhibition at the Cleveland Museum of Art
Academia.edu no longer supports Internet Explorer. To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
Is Failure Central to the Architectural Profession?
Thanks to Charles Jencks, the demolition of Pruitt-Igoe is regularly cited as the moment when the modernist dream ended. The blame for this failure is habitually placed on the doorstep of the architects and planners; however, factors other than the architecture were often behind the social problems experienced by residents of mass-social housing. Why is it then that you rarely hear architects defend the architecture? The destruction of Pruitt-Igoe.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack